AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 21 min read$PCVX

Wassil Jim sold $212K of PCVX

Wassil Jim (CHIEF OPERATING OFFICER) sold 3,477 shares of Vaxcyte, Inc. (PCVX) at an average of $61.07 ($60.89–$61.48, $0.21M total) across 4 trades on 2026-09-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Wassil Jim
Published Sep 2, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 3, 2026, 7:39 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PCVX
Neutral
high confidence
Mentioned
$PCVX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PCVXNeutralLow
01

Why it matters

The disclosed insider sale is modest and pre‑arranged, offering little new insight for traders.

02

Market read

Routine insider transaction with minimal trading relevance.

03

What to watch

The sale follows a 10b5‑1 plan, reducing the likelihood of negative information.

Relevance 3/10Novelty 4/10Timing: post‑market filing on Sep 1

Background

Vaxcyte (PCVX) is a Nasdaq‑listed biotech developing vaccine technologies.

Company-level read

Ticker impact

$PCVXNeutralHigh confidence
Context

COO Wassil Jim sold 3,477 shares for $212K via a 10b5‑1 plan, reducing his stake to 155,041 shares.

Expected impact

No significant impact expected; price may stay flat.

Evidence & confidence

Sale size is small relative to market cap and disclosed via pre‑arranged plan, indicating no urgent information.

Market effects

Sector

None; Vaxcyte operates in biotech where insider sales are routine.

Regional

No regional effect.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

If the COO is reducing exposure, it could signal concerns about upcoming data.

Key entities

  • Officer
    Wassil Jim

    Chief Operating Officer of Vaxcyte

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PCVX insider trading history →

Related articles

SEP 6
$PCVXMed

The Next Year Will Define Vaxcyte’s (PCVX) Vaccine Gamble

Vaxcyte (PCVX) reported a near-doubled net loss of $284.3M in Q2, with key Phase 3 trial results for its pneumococcal vaccine candidate VAX-31 expected by late 2026. The company has $2.5B in cash and added vaccine industry veterans to its board. Success hinges on upcoming clinical data.

yahoo.com3 min
AUG 5
$PCVXMed

Vaxcyte, Inc. (PCVX): Results of Operations and Financial Condition

Vaxcyte, Inc. (PCVX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Adult Phase 3 OPUS-1 Trial Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Phase 3 Results Expected in First Half

SEC EDGAR 8-K6 min